Incidence and Risk Factors for Infections in Patient Treated With Corticosteroids, Immunosuppressive Drugs or Biotherapy for Immunologic and Inflammatory Diseases (INFIM)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02280902|
Recruitment Status : Recruiting
First Posted : November 2, 2014
Last Update Posted : March 23, 2020
Infections represent the first cause of death and of morbidity in people treated for immunologic and inflammatory diseases with corticosteroids, immunosuppressive drugs or biotherapy. Epidemiological, clinical, biological and therapeutic determinants of these infections are poorly understood. There is no recommendation for the prevention and treatment of infections in this particular field.
Purpose : Recent therapeutic trials evaluating immunosuppressive and biotherapy (cyclophosphamide, mycophenolate mofetil, rituximab, belimumab) in the field of immunologic and inflammatory diseases have found a risk of severe infection of 7 to 18% during the first year after the beginning of the treatment. Thus, the main objective of the study is to describe the incidence and risk-factors for infections in people treated with such agents for immunologic and inflammatory diseases.
|Condition or disease||Intervention/treatment|
|Immunologic and Inflammatory Diseases||Biological: Blood samples|
Monitoring of neutrophils, lymphocytes, immune activation markers, immunoglobulins have not been prospectively studied in such patients. Preliminary retrospective studies have shown that total lymphopenia was independently associated with an increased risk of infections. A previous retrospective study from our group have also shown that total lymphopenia and CD3- lymphopenia three months after the beginning of rituximab was associated with infections.
The determinants of infections occurring during the course of immune and inflammatory diseases treated with corticoids and immunosuppressive drugs or biotherapy are probably multiples. We hypothesized that the following variables may have an impact on the risk of infections in those patients: Epidemiological: gender, social situation, Clinical: causal disease, comorbidities, vaccination status, Therapeutic: type and doses of corticosteroids and immunosuppressive drugs/biotherapy, prevention treatment Biological : neutrophils, total lymphocytes, CD4-T lymphocytes, CD8-T lymphocytes, B lymphocytes, immune activation (HLA-DR+ lymphocytes), CD5 and CD19 lymphocytes, CD27/IgD lymphocytes, immunoglobulins IgA, IgM, IgG.
On the other side, the impact of infection on the clinical course of immunologic or inflammatory disease have been poorly described and will be documented by this longitudinal study.
After inclusion in the present study, patients will be followed on a 30 months period and monitored at M3, M6, M12, M24 to describe the impact of treatment on clinical and biological variables. Every clinical event will be prospectively reported and validated by a specific committee.
|Study Type :||Observational|
|Estimated Enrollment :||217 participants|
|Official Title:||Incidence and Risk Factors for Infections in Patient Treated With Corticosteroids, Immunosuppressive Drugs or Biotherapy for Immunologic and Inflammatory Diseases|
|Actual Study Start Date :||February 16, 2016|
|Estimated Primary Completion Date :||June 2021|
|Estimated Study Completion Date :||June 2021|
Patient with immunologic and inflammatory diseases
Patient treated with corticosteroids, immunosuppressive drugs or biotherapy for immunologic and inflammatory diseases
Biological: Blood samples
Systematic follow-up (M3, M6, M12, M18, M24, M30) will be implemented to complete epidemiologic, clinical, therapeutic and biological data during a 30 months period. Specific measure of immune cells, markers of immune activation, immunoglobulins as described above will be performed at M3, M6, M12 and M24. A biologic collection (serum and cells) will be performed at the same time points for future prognostic studies.
- Viral, bacterila, fungal or parasitic infection leading to hospitalization [ Time Frame: 30 months after the inclusion ]
- Biological and immunological markers [ Time Frame: Each 6 months from baseline for 30 months ]
The following items will be assessed every 6 months :
total White blood cell CD3 CD4 CD8 HLA-DR+ B cells CD19+ B cells CD5+/- CD27/IgD NK cells IgA, IgM, IgG levels
- Morbidity [ Time Frame: Each 6 months from baseline for 30 months ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02280902
|Contact: Fabrice BONNET, Prof.||(0) 556795826 ext +firstname.lastname@example.org|
|Service de Médecine Interne - CH d'Agen||Not yet recruiting|
|Agen, France, 47923|
|Contact: Patrick RISPAL, MD email@example.com|
|Principal Investigator: Patrick RISPAL, MD|
|Service de Médecine Interne et maladies Infectieuses - Hôpital Saint-André||Recruiting|
|Bordeaux, France, 33075|
|Contact: Fabrice BONNET, Prof. (0)5 56 79 58 26 ext +33 firstname.lastname@example.org|
|Principal Investigator: Fabrice BONNET, Prof.|
|Sub-Investigator: Partick MERCIE, Prof.|
|Sub-Investigator: Julien SENESCHAL, MD|
|Sub-Investigator: Jean-François VIALLARD, Prof.|
|Sub-Investigator: Pierre MERVILLE, Prof.|
|Sub-Investigator: Christophe RICHEZ, MD|
|service de médecine interne - CH de Libourne||Not yet recruiting|
|Contact: Olivier CAUBET, MD email@example.com|
|Service de Médecine Interne - CHU de Limoges||Not yet recruiting|
|Limoges, France, 87042|
|Contact: Guillaume GONDRAN, MD firstname.lastname@example.org|
|Principal Investigator: Guillaune GONDRAN, MD|
|Service de Médecine Interne - CH de Pau||Not yet recruiting|
|Pau, France, 64000|
|Contact: Xavier DELBREL, MD email@example.com|
|Principal Investigator: Xavier DELBREL, MD|
|service Médecine Interne - CHU de Toulouse - Hôpital Purpan (5)||Recruiting|
|Toulouse, France, 31300|
|Contact: Laurent SAILLER, Prof. firstname.lastname@example.org|
|Principal Investigator: Laurent SAILLER, Prof.|
|service Médecine Interne - CHU de Toulouse - Hôpital Purpan (7)||Not yet recruiting|
|Contact: Laurent ALRIC, Prof email@example.com|
|Principal Investigator:||Fabrice BONNET, Prof.||University Hospital Bordeaux, France|
|Study Chair:||Rodolphe THIEBAUT, Prof.||University Hospital Bordeaux, France|